Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 12/20 | 0.50 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488317 | 0.79 | P4HTM (0.53) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL2300999 | 0.79 | P4HTM (0.53) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL6852624 | 0.79 | CA1 (0.40) | P4HTMP4HA1CXCR2CXCR1 | |
| SCHEMBL7952665 | 0.77 | CA1 (0.39) | ALDH1A1L3MBTL1CXCR2CXCR1 | |
| SCHEMBL287075 | 0.77 | P4HTM (0.58) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL10329128 | 0.77 | P4HTM (0.50) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL17162305 | 0.77 | P4HTM (0.54) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL752015 | 0.76 | CXCR2 (0.39) | CXCR2CXCR1 | |
| SCHEMBL8804385 | 0.75 | CXCR2 (0.37) | CXCR2CXCR1 | |
| SCHEMBL17520868 | 0.75 | P4HTM (0.49) | P4HTMP4HA1MIFKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | P4HTM 368/4885P4HA1 215/4885MIF 1177/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | P4HTM 357/4885P4HA1 314/4885MIF 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.